MedTrace Logo

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

NCT00178841 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2016-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine if combination therapy with rosiglitazone and bexarotene might have a synergistic effect in the treatment of patients with CTCL.

Conditions

  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

DRUG

Rosiglitazone and Bexarotene

rosiglitazone added to bexarotene capsules

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • John A Zic, MD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00178841 on ClinicalTrials.gov